Traditionally, FET::CREB fusions have been limited to a triad of distinctive soft tissue neoplastic entities defined by variable combination of clinicopathological, morphological, and immunophenotypical characteristics: clear cell sarcoma of soft tissue (CCS; predominantly EWSR1::ATF1 fused [5]), angiomatoid fibrous histiocytoma (AFH; predominantly EWSR1::CREB1 fused [6]), and malignant gastrointestinal neuroectodermal tumor (MGNET; predominantly EWSR1::ATF1 fused [7]). Here, ATF1 is linked to clear cell sarcoma.